SCHEMBL3634210

SCHEMBL3634210

NC(=O)c1ccc(C2CCN(C(=O)C3CC3)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 5/20 0.55
CYP2C9 P11712 2/20 0.49
PARP14 Q460N5 3/20 0.48
SLC9A1 P19634 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
HRH3 Q9Y5N1 2/20 0.47
HTR2B P41595 1/20 0.46
NAMPT P43490 2/20 0.45
MCHR1 Q99705 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
DGAT1 O75907 1/20 0.43
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635417 0.94 PARP10 (0.53) PARP10CYP2C9PARP14SLC9A1HRH3
SCHEMBL3303476 0.91 PARP10 (0.48) PARP10CYP2C9PARP14SLC9A1CYP3A4
SCHEMBL3304709 0.91 HPGD (0.51) PARP10CYP2C9HRH3HTR2BMEN1
SCHEMBL3631718 0.90 PARP10 (0.52) PARP10CYP2C9PARP14SLC9A1CYP3A4
SCHEMBL3633148 0.88 PARP10 (0.51) PARP10CYP2C9PARP14SLC9A1CYP3A4
SCHEMBL3297761 0.87 HTT (0.50) PARP10CYP2C9HRH3NAMPTMCHR1
SCHEMBL3303976 0.87 POLB (0.49) PARP10CYP2C9HRH3NAMPTDGAT1
SCHEMBL3635174 0.85 NAMPT (0.59) PARP10PARP14NAMPTDGAT1
SCHEMBL3634211 0.84 SLC18A3 (0.49) HTR2BNAMPTDGAT1HPGD
SCHEMBL7371984 0.84 PARP10 (0.58) PARP10CYP2C9PARP14HRH3NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155687-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2010-02-24 EP claimed
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors VIA PHARMACEUTICALS, INC. 2009-04-16 US claimed
WO-2008141976-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2008-11-27 WO claimed
EP-2155687-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2010-02-24 EP disclosed
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-07-02 US disclosed
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-23 US disclosed
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors VIA PHARMACEUTICALS, INC. 2009-04-16 US disclosed
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-09 US disclosed
WO-2008141976-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT PARP10 1539/4885CYP2C9 1204/4885PARP14 1803/4885
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT PARP10 1539/4885CYP2C9 1204/4885PARP14 1803/4885
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT PARP10 1539/4885CYP2C9 1204/4885PARP14 1803/4885
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT PARP10 1539/4885CYP2C9 1204/4885PARP14 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.